Comparative Pharmacology
Head-to-head clinical analysis: DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM versus OMNIPAQUE 12.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM versus OMNIPAQUE 12.
DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM vs OMNIPAQUE 12
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Radiopaque contrast agent that attenuates X-rays, providing visualization of vascular and urinary structures. It is a high-osmolality ionic dimer that distributes in extracellular fluid and is excreted renally.
Radiopaque agent that attenuates X-rays, providing contrast in imaging. Iodine atoms absorb X-rays, enhancing visualization of blood vessels and tissues.
Intra-arterial or intravenous administration; adult dose varies by procedure: for intravenous urography, 50-100 mL of 60% solution; for CT enhancement, 100-150 mL of 60% solution; maximum total dose 4.2 g iodine/kg body weight.
Adult dose: 12 g iodine (e.g., 200 mL of Omnipaque 12) administered intravenously, intra-arterially, or into body cavities. Typical contrast study dose: 1-2 mL/kg (max 150 mL) for CT; 40-60 mL for angiographic procedures.
None Documented
None Documented
1-2 hours in normal renal function; prolonged in renal impairment (up to 20-30 hours in severe impairment)
1-2 hours (normal renal function); prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min)
Renal: >95% unchanged via glomerular filtration; biliary/fecal: <5%
Renal: >95% unchanged; biliary/fecal: <5%
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent